• 1
    Karpoff HM, D'Angelica M, Blair S, Brownlee MD, Federoff H, Fong Y. Prevention of hepatic tumor metastases in rats with herpes viral vaccines and gamma-interferon. J Clin Invest 1997; 99: 799804.
  • 2
    Fong Y, Sun RL, Jarnagin W, Blumgart LH. An analysis of 412 cases of hepatocellular carcinoma at a Western center. Ann Surg 1999; 229: 790799.
  • 3
    Delman K, Bennett JJ, Zager JS, Burt BM, McAuliffe PF, Petrowsky H, et al. Effects of preexisting immunity on the response to herpes simplex-based oncolytic viral therapy. Hum Gene Ther 2000; 11: 24652472.
  • 4
    Fong Y, Cohen AM, Fortner JG, Morrerro A, Prassad M, Blumgart LH, et al. Liver resection for colorectal metastases. J Clin Oncol 1997; 15: 938946.
  • 5
    Picardo A, Karpoff HM, Ng B, Lee J, Brennan MF, Fong Y. Partial hepatectomy accelerates local tumor growth: potential roles of local cytokine activation. Surgery 1998; 124: 5764.
  • 6
    Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 1999; 230: 309318.
  • 7
    Yoon SS, Carroll NM, Chiocca EA, Tanabe KK. Cancer gene therapy using a replication-competent herpes simplex virus type 1 vector. Ann Surg 1998; 228: 366374 [erratum: Ann Surg 1998;228(5):following table of contents].
  • 8
    Yoon SS, Nakamura H, Carroll NM, Bode BP, Chiocca EA, Tanabe KK. An oncolytic herpes simplex virus type 1 selectively destroys diffuse liver metastases from colon carcinoma. FASEB J 2000; 14: 301311.
  • 9
    Goldstein DJ, Weller SK. Factor(s) present in herpes simplex virus type 1-infected cells can compensate for the loss of the large subunit of the viral ribonucleotide reductase: characterization of an ICP6 deletion mutant. Virology 1988; 166: 4151.
  • 10
    Cozzi PJ, Malhotra S, McAuliffe P, Kooby DA, Federoff HJ, Huryk B, et al. Intravesical oncolytic viral therapy using attenuated, replication-competent herpes simplex viruses G207 and Nv1020 is effective in the treatment of bladder cancer in an orthotopic syngeneic model. FASEB J 2001; 15: 13061308.
  • 11
    Kooby DA, Carew JF, Halterman MW, Mack JE, Bertino JR, Blumgart LH, et al. Oncolytic viral therapy for human colorectal cancer and liver metastases using a multimutated herpes simplex virus type-1 (G207). FASEB J 1999; 6: 499504.
  • 12
    Bennett JJ, Kooby DA, Delman K, McAuliffe P, Halterman MW, Federoff H, et al. Antitumor efficacy of regional oncolytic viral therapy for peritoneally disseminated cancer. J Mol Med 2000; 78: 166174.
  • 13
    Todo T, Rabkin SD, Sundaresan P, Wu A, Meehan KR, Herscowitz HB, et al. Systemic antitumor immunity in experimental brain tumor therapy using a multimutated, replication-competent herpes simplex virus. Hum Gene Ther 1999; 10: 27412755.
  • 14
    Toda M, Rabkin SD, Martuza RL. Treatment of human breast cancer in a brain metastatic model by G207, a replication-competent multimutated herpes simplex virus 1. Hum Gene Ther 1998; 9: 21772185.
  • 15
    Walker JR, McGeagh KG, Sundaresan P, Jorgensen TJ, Rabkin SD, Martuza RL. Local and systemic therapy of human prostate adenocarcinoma with the conditionally replicating herpes simplex virus vector G207. Hum Gene Ther 1999; 10: 22372243.
  • 16
    Markert JM, Medlock MD, Rabkin SD, Gillespie GY, Todo T, Hunter WD, et al. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther 2000; 7: 867874.
  • 17
    Mineta T, Rabkin SD, Yazaki T, Hunter WD, Martuza RL. Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat Med 1995; 1: 938943.
  • 18
    Mann GJ, Musgrove EA, Fox RM, Thelander L. Ribonucleotide reductase M1 subunit in cellular proliferation, quiescence, and differentiation. Cancer Res 1988; 48: 51515156.
  • 19
    Petrowsky H, Roberts GD, Kooby DA, Burt BM, Bennett JJ, Delman KA, et al. Functional interaction between fluorodeoxyuridine-induced cellular alterations and replication of a ribonucleotide reductase-negative herpes simplex virus. J Virol 2001; 75: 70507058.
  • 20
    Meignier B, Longnecker R, Roizman B. In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020: construction and evaluation in rodents. J Infect Dis 1988; 158: 602614.
  • 21
    Meignier B, Martin B, Whitley RJ, Roizman B. In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020. II. Studies in immunocompetent and immunosuppressed Owl monkeys (Aotus trivirgatus). J Infect Dis 1990; 162: 313321.
  • 22
    Higgins G, Anderson R. Experimental pathology of the liver. I. Restoration of the liver of the white rat following partial surgical removal. Arch Pathol 1931; 12: 186202.
  • 23
    Bradford M. A rapid and sensitive method for quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248254.
  • 24
    Knotts FB, Cook ML, Stevens JG. Pathogenesis of herpetic encephalitis in mice after ophthalmic inoculation. J Infect Dis 1974; 130: 1627.
  • 25
    Goldstein DJ, Weller SK. Herpes simplex virus type 1-induced ribonucleotide reductase activity is dispensable for virus growth and DNA synthesis: isolation and characterization of an ICP6 lacZ insertion mutant. J Virol 1988; 62: 196205.
  • 26
    Jacobson JG, Leib DA, Goldstein DJ, Bogard CL, Schaffer PA, Weller SK, et al. A herpes simplex virus ribonucleotide reductase deletion mutant is defective for productive acute and reactivatable latent infections of mice and for replication in mouse cells. Virology 1989; 173: 276283.
  • 27
    Goldstein DJ, Weller SK. An ICP6::lacZ insertional mutagen is used to demonstrate that the UL52 gene of herpes simplex virus type 1 is required for virus growth and DNA synthesis. J Virol 1988; 62: 29702977.
  • 28
    Yazaki T, Manz HJ, Rabkin SD, Martuza RL. Treatment of human malignant meningiomas by G207, a replication-competent multimutated herpes simplex virus 1. Cancer Res 1995; 55: 47524756.
  • 29
    Kemeny N, Huang Y, Cohen AM, Shi W, Conti JA, Brennan MF, et al. Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. N Engl J Med 1999; 341: 20392048.
  • 30
    Hunter WD, Martuza RL, Feigenbaum F, Todo T, Mineta T, Yazaki T, et al. Attenuated, replication-competent herpes simplex virus type 1 mutant G207: safety evaluation of intracerebral injection in nonhuman primates. J Virol 1999; 73: 63196326.
  • 31
    Hoyle RM, Banes A, Bernard S, Thomas CG Jr. Effects of 2′-deoxy-5-fluorouridine on regenerating liver following partial hepatectomy in the rat. J Surg Res 1988; 45: 181186.
  • 32
    Ryan CJ, Wood CB, Blumgart LH. The effect of 5-fluorouracil on DNA synthesis in the rat liver undergoing compensatory hyperplasia after partial hepatectomy. Clin Oncol 1983; 9: 4349.
  • 33
    Grosfeld JL, Weber TR, Baehner RL. Comparative toxicity of chemotherapy following partial hepatectomy. J Pediatr Surg 1981; 16: 950954.
  • 34
    Nabel GJ, Gordon D, Bishop DK, Nickoloff BJ, Yang ZY, Aruga A, et al. Immune response in human melanoma after transfer of an allogeneic class I major histocompatibility complex gene with DNA-liposome complexes. Proc Natl Acad Sci U S A 1996; 93: 1538815393.
  • 35
    Rainov NG, Burkert W. Miliary brain metastases from malignant melanoma. Zentralblatt fur Neurochirurgie 1996; 57: 2024.
  • 36
    Michalopoulos GK, DeFrances MC. Liver regeneration. Science 1997; 276: 6066.
  • 37
    Lambotte L, Saliez A, Triest S, Tagliaferri EM, Barker AP, Baranski AG. Control of rate and extent of the proliferative response after partial hepatectomy. Am J Physiol 1997; 273: G905G912.
  • 38
    Assy N, Gong Y, Zhang M, Pettigrew NM, Pashniak D, Minuk GY. Use of proliferating cell nuclear antigen as a marker of liver regeneration after partial hepatectomy in rats. J Lab Clin Med 1998; 131: 251256.
  • 39
    Gerlach C, Sakkab DY, Scholzen T, Dassler R, Alison MR, Gerdes J. Ki-67 expression during rat liver regeneration after partial hepatectomy. HEPATOLOGY 1997; 26: 573578.
  • 40
    King CD, Van Lancker JL. Molecular mechanisms of liver regeneration. VII. Conversion of cytidine to deoxycytidine in rat regenerating livers. Arch Biochem Biophys 1969; 129: 603608.
  • 41
    Labow R, Maley GF, Maley F. The effect of methotrexate on enzymes induced following partial hepatectomy. Cancer Res 1969; 29: 366372.
  • 42
    Larsson A. Ribonucleotide reductase from regenerating rat liver. Eur J Biochem 1969; 11: 113121.
  • 43
    Kooby DA, Zakian KL, Challa SN, Matei C, Petrowsky H, Yoo HH, et al. Use of phosphorous-31 nuclear magnetic resonance spectroscopy to determine safe timing of chemotherapy after hepatic resection. Cancer Res 2000; 60: 38003806.